Atrium Therapeutics, Inc. (RNA) EBITDA
Atrium Therapeutics, Inc. (RNA) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$22.62M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$17.28M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$12.86M; Depreciation and amortization (m).
- 2025-03-31: Basis Reported; EBITDA (m); Operating income -$7.45M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | (m) | -$22.62M | (m) | $3.00M | (m) | $36.00K* | -$3.93M* | (m) | $15.34M | (m) | (m) |
|---|
| 2026-03-31 | Reported | (m) | -$17.28M | (m) | $19.64M | (m) | $2.10M | -$31.14M | (m) | $16.66M | (m) | (m) |
|---|
| 2025-06-30 | Reported | (m) | -$12.86M | (m) | $3.85M | (m) | $266.00K* | -$11.91M* | (m) | $13.29M | (m) | (m) |
|---|
| 2025-03-31 | Reported | (m) | -$7.45M | (m) | $1.57M | (m) | $0.00 | -$11.10M | (m) | $6.94M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|